21-23 August 2017

Boston, MA, USA

Limited places remaining 

Transforming Discovery & Translational Fibrosis Research into Disease Modifying IPF Therapeutics

The inaugural Idiopathic Pulmonary (IPF) Summit is the only event solely dedicated to transforming discovery & translational fibrosis research into disease modifying IPF therapeutics,

This unique IPF meeting is your opportunity to join the leading minds across biopharma and academia to reduce the expansive translational gap that exists in current IPF drug development.

With more than 40 organizations already in attendance and limited place remaining, now is the time to secure your place.

Don’t miss your opportunity to share insights and network with the key players, including Bristol-Myers Squibb, Genentech, Patara Pharma Inc, Boehringer Ingelheim, Promedior and FibrogenAcross 3 jam-packed days the brightest minds will be sharing their insight and lessons learned to collectively enable the community to:

  • Effectively translate into the clinic by better recapitulating IPF through robust in vitro & vivo models
  • Define more meaningful preclinical endpoints to aid identification of novel targets and development of more effective IPF therapeutics
  • Validate non-invasive biomarker & diagnostic techniques for back translation and ultimately achieve greater clinical benefit

Join your peers in Boston to overcome the challenges that are preventing you from accelerating the development of your IPF candidate.

Find out more.

"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!” AstraZeneca - Previous Hanson Wade Life Sciences event attendee

This  Summit is for:

  • Large Pharma
  • Biotech
  • Academics looking to
    network with industry
  • Preclinical model providers
  • CROs
IPF Boehringer Ingelheim
register widget homepage

 

 

 

 

 

Media Partner